{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:00:58Z","timestamp":1769763658216,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,13]]},"DOI":"10.7759\/cureus.46985","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:16:58Z","timestamp":1697217418000},"source":"Crossref","is-referenced-by-count":2,"title":["Thyroid Storm and Type 1 Diabetes Mellitus Induced by Combined Ipilimumab and Nivolumab Immunotherapy: A Case Report"],"prefix":"10.7759","author":[{"given":"Vivek","family":"Ramburuth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeyanthy","family":"Rajkanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2014.5.6.3","article-title":"Immune checkpoint blockade: a new paradigm in treating advanced cancer","volume":"5","author":"Kreamer KM","year":"2014","unstructured":"Kreamer KM. Immune checkpoint blockade: a new paradigm in treating advanced cancer. J Adv Pract Oncol. 2014, 5:418-31. 10.6004\/jadpro.2014.5.6.3","journal-title":"J Adv Pract Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015, 373:23-34. 10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and Ipilimumab in advanced melanoma","volume":"377","author":"Wolchok JD","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al.. Overall survival with combined nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017, 377:1345-56. 10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01671","article-title":"Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials","volume":"10","author":"Da L","year":"2019","unstructured":"Da L, Teng Y, Wang N, Zaguirre K, Liu Y, Qi Y, Song F. Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials. Front Pharmacol. 2019, 10:1671. 10.3389\/fphar.2019.01671","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:173-82. 10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211058393","article-title":"Adverse events induced by nivolumab and ipilimumab combination regimens","volume":"14","author":"Somekawa K","year":"2022","unstructured":"Somekawa K, Horita N, Kaneko A, et al.. Adverse events induced by nivolumab and ipilimumab combination regimens. Ther Adv Med Oncol. 2022, 14:17588359211058393. 10.1177\/17588359211058393","journal-title":"Ther Adv Med Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt Z","year":"2020","unstructured":"Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol. 2020, 200:131-40. 10.1111\/cei.13424","journal-title":"Clin Exp Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-018-1708-x","article-title":"Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report","volume":"12","author":"Yonezaki K","year":"2018","unstructured":"Yonezaki K, Kobayashi T, Imachi H, et al.. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report. J Med Case Rep. 2018, 12:171. 10.1186\/s13256-018-1708-x","journal-title":"J Med Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky021","article-title":"The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management","volume":"2","author":"Girotra M","year":"2018","unstructured":"Girotra M, Hansen A, Farooki A, et al.. The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr. 2018, 2:pky021. 10.1093\/jncics\/pky021","journal-title":"JNCI Cancer Spectr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2478\/jtim-2022-0009","article-title":"Immune checkpoint inhibitor-related endocrinopathies","volume":"10","author":"Lu D","year":"2022","unstructured":"Lu D, Gao Y. Immune checkpoint inhibitor-related endocrinopathies. J Transl Int Med. 2022, 10:9-14. 10.2478\/jtim-2022-0009","journal-title":"J Transl Int Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer PC","year":"2018","unstructured":"Iyer PC, Cabanillas ME, Waguespack SG, et al.. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid. 2018, 28:1243-51. 10.1089\/thy.2018.0116","journal-title":"Thyroid"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli AM","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL, et al.. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018, 67:1471-80. 10.2337\/dbi18-0002","journal-title":"Diabetes"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman K","year":"2018","unstructured":"Clotman K, Janssens K, Specenier P, Weets I, De Block CE. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab. 2018, 103:3144-54. 10.1210\/jc.2018-00728","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni A","year":"2022","unstructured":"Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol. 2022, 13:779691. 10.3389\/fimmu.2022.779691","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/193034-thyroid-storm-and-type-1-diabetes-mellitus-induced-by-combined-ipilimumab-and-nivolumab-immunotherapy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:00Z","timestamp":1707509340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/193034-thyroid-storm-and-type-1-diabetes-mellitus-induced-by-combined-ipilimumab-and-nivolumab-immunotherapy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.46985","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}